L’entreprise pharmaceutique Advicenne se lance sur Euronext Paris

IPO raises €27 million; market capitalisation €112 million

Paris – 6 December 2017 – Advicenne, a pharmaceutical SME from the south of France at advanced stages of development, today celebrated its first day of trading on Euronext Paris. Funds raised through listing will help the company pursue clinical development of its leading product in Europe and the United States, and finance commercial growth in Europe.

Founded in Nîmes in 2007 by Dr Luc-André Granier, MD, and Caroline Roussel-Petit, respectively Chairman & CEO and Director of Operations, Advicenne develops therapeutic products for children and adults suffering from rare renal and neurological diseases. From the start, the company has been backed by leading venture capital investors including InnoBio (Bpifrance), IXO Private Equity, IRDI Soridec Gestion, Cemag Invest and MI Care, as well as private investors.

Advicenne (ticker code ADVIC) was listed through the admission to trading on 6 December 2017 of 8,002,696 shares making up the company’s equity, including 2,007,718 new shares (after partial exercise of the extension clause and before exercise of the overallotment option), raising a total of €27 million euros, and may rise to €28.2 million euros in case of full-exercise of the over-allotment option.

The offering price was set at €14,03 per share and market capitalisation was around €112 million on the day of listing.

At the listing ceremony, the company’s co-founder, Chairman & CEO Dr. Luc-André Granier, said: “We are delighted to have completed our initial public offering on Euronext Paris, and to welcome new investors alongside our historical shareholders, who have confirmed their ongoing support for our team and our work. We would like to thank each and every one, both individuals and institutions, for placing their trust in Advicenne. This IPO represents a milestone in our strategy, and will enable us to pursue the clinical development of our lead product in both Europe and the United States, and lay the groundwork for its planned commercialisation in Europe in 2020.”

Télécharger le communiqué de presse

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.